Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4527310 | 0.83 | RARA (0.37) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL4507783 | 0.76 | RARA (0.37) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL4507831 | 0.74 | RARA (0.38) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL4516928 | 0.70 | RARB (0.39) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL4504943 | 0.69 | FFAR1 (0.35) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL4518425 | 0.69 | CYP26A1 (0.37) | CYP3A4RARARARBRARGFFAR1 | |
| SCHEMBL5737841 | 0.68 | RARB (0.37) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL4504758 | 0.67 | RARA (0.38) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL4517141 | 0.66 | FFAR1 (0.43) | FFAR1FFAR4 | |
| SCHEMBL5737713 | 0.64 | AKR1B1 (0.37) | CYP3A4RARARARBRARGKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | CYP3A4 16/4885RARA 528/4885RARB 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.